ImClone Closing Branchburg, New Jersey Manufacturing Facility
08/17/2010
"This decision was made after careful consideration of a number of internal and external factors related to Erbitux [a cancer drug]," said Janice Chavers, an Eli Lilly spokesperson. "The decision was not driven by Lilly's larger restructuring effort."
ImClone currently has 90 open positions for which employees affected by the layoffs will have priority. The closure plans are effective immediately.
Project Announcements
OgMentum ARK Plans Bowling Green, Kentucky, Headquarters-R&D Operations
09/13/2025
Damotech Expand Moberly, Missouri, Operations
09/11/2025
Canada-Based Endurance Technologies Plans Las Cruces, New Mexico, Manufacturing Operations
09/11/2025
Nathan Trotter Plans Henry County, Virginia, Metal Processing Operations
09/11/2025
Samuel Son & Co. Expands Baltimore, Maryland, Operations
09/11/2025
American Rheinmetall Plans Auburn Hills, Michigan, Headquarters Operations
09/11/2025
Most Read
-
Tariffs, Talent, and U.S. Expansion
Q3 2025
-
What We’re Getting Wrong About Gen Z’s Future in the Skilled Trades
Q3 2025
-
Data Center Demand Stabilizes Amid Changing Market Forces
Q3 2025
-
Powering the Next Generation of Projects
Q3 2025
-
A New Course for U.S. Shipbuilding
Q3 2025
-
How Consumer Trends Are Reshaping Food Facilities
Q3 2025
-
Optimizing Your Rail-Served Transportation Network: Strategy Before Steel
Q2 2025